Opioid antagonist challenges in buprenorphine maintained patients.

  title={Opioid antagonist challenges in buprenorphine maintained patients.},
  author={Thomas R. Kosten and John H. Krystal and Dennis S. Charney and Lawrence H. Price and C. H. Morgan and Herbert D. Kleber},
  journal={Drug and alcohol dependence},
  volume={25 1},
Following one month of sublingual buprenorphine treatment, 15 patients at either 2 mg (n = 7) or 3 mg (n = 8) were hospitalized and the buprenorphine was abruptly stopped by placebo substitution. On the morning following their last dose of buprenorphine, 10 patients were given 1 mg oral naltrexone and 5 were given 0.5 mg/kg intravenous naloxone in a double blind placebo controlled challenge. The naltrexone challenges produced no increase in opioid withdrawal symptoms, plasma MHPG levels, or… CONTINUE READING

From This Paper

Topics from this paper.


Publications citing this paper.
Showing 1-10 of 14 extracted citations

Buprenorphine Therapy of Opiate Addiction

Steven B. Kareh
Forensic Science and Medicine • 2002
View 3 Excerpts

Similar Papers

Loading similar papers…